Compassionate use of mirdametinib for serious conditions
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This program provides access to an investigational drug called mirdametinib for people with serious, debilitating, or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer a potential treatment when nothing else has worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious, debilitating, or life-threatening condition.
- Your condition cannot be adequately treated with approved medicines or standard treatments.
- You have exhausted all other treatment options.
- You do not qualify for any ongoing clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
This program provides access to an unapproved drug called nirogacestat for patients with serious conditions who have run out of standard treatment options. It is designed for compassionate use when no other trial is available.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Hear when a new Neurofibromatosis Type 1-Associated Plexiform Neurofibromas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.